Rationale and Design of EMPOWER, a Pragmatic Randomized Trial of Automated Hovering in Patients With Congestive Heart Failure

被引:10
|
作者
Mehta, Shivan J. [1 ,2 ,3 ]
Volpp, Kevin G. [1 ,2 ,3 ]
Asch, David A. [1 ,2 ,3 ]
Goldberg, Lee R. [1 ,2 ]
Russell, Louise B. [1 ,2 ]
Norton, Laurie A. [1 ,2 ]
Iannotte, Lauren G. [1 ,2 ]
Troxel, Andrea B. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Hlth Policy & Med Eth, Philadelphia, PA 19104 USA
[3] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[4] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2019年 / 12卷 / 04期
关键词
disease management; health care cost; heart failure; morbidity; mortality; HEALTH; HOSPITALIZATION; MANAGEMENT; ADHERENCE; OUTCOMES; RISK; MORTALITY; PATTERNS; SURVIVAL; MODEL;
D O I
10.1161/CIRCOUTCOMES.118.005126
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Congestive heart failure is a major cause of morbidity, mortality, and cost. Disease management programs have shown promise but lack firm evidence of effectiveness and scalability. We describe the motivation, design, and planned analyses of EMPOWER (Electronic Monitoring of Patients Offers Ways to Enhance Recovery), a randomized clinical trial of an innovative intervention incorporating behavioral economic principles with remote monitoring technology embedded within a healthcare system. METHODS AND RESULTS: EMPOWER is an ongoing, pragmatic, randomized clinical trial comparing usual care to an automated hovering intervention that includes patient-level incentives for daily weight monitoring and diuretic adherence combined with automated feedback into the clinical care pathway, enabling real-time response to concerning clinical symptoms. Identification of eligible patients began in May 2016, and implementation of the intervention is feasible. Trial processes are embedded into existing clinical pathways. The primary outcome is time to readmission for any cause. Cost-effectiveness analyses are planned to evaluate the healthcare costs and health outcomes of the approach. CONCLUSIONS: The EMPOWER trial incorporates leading-edge approaches in human motivation, derived from behavioral economics, with contemporary technology to provide scale and exception handling at low cost. The trial is also implemented within the naturalized environment of a health system, as much as possible taking advantage of the existing journeys of patients and workflows of clinicians. A goal of this pragmatic design is to limit resource utilization and also to test an intervention that would need minimal modification to be translated from research into a new way of practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Diuretic titration based on weight change in decompensated congestive heart failure: A randomized trial
    Cardoso, J. N.
    Ochiai, M. E.
    Oliveira, M. T.
    Reis, C. M.
    Curiati, M.
    Vieira, K. R.
    Barretto, A. C. P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 3020 - 3021
  • [32] Design of a bilevel clinical trial targeting adherence in heart failure patients and their providers: The Congestive Heart Failure Adherence Redesign Trial (CHART)
    Mangla, Ashvarya
    Doukky, Rami
    Richardson, DeJuran
    Avery, Elizabeth F.
    Dawar, Rebecca
    Calvin, James E., Jr.
    Powell, Lynda H.
    AMERICAN HEART JOURNAL, 2018, 195 : 139 - 150
  • [33] Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
    Jensen, Jesper
    Omar, Massar
    Kistorp, Caroline
    Poulsen, Mikael Kjaer
    Tuxen, Christian
    Gustafsson, Ida
    Kober, Lars
    Gustafsson, Finn
    Fosbol, Emil
    Bruun, Niels Eske
    Videbaek, Lars
    Frederiksen, Peter Hartmund
    Moller, Jacob Eifer
    Schou, Morten
    TRIALS, 2019, 20 (1)
  • [34] Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure
    Abraham, William T.
    Ponikowski, Piotr
    Brueckmann, Martina
    Zeller, Cordula
    Macesic, Hemani
    Peil, Barbara
    Brun, Michele
    Ustyugova, Anastasia
    Jamal, Waheed
    Salsali, Afshin
    Lindenfeld, Joann
    Anker, Stefan D.
    Abraham, William
    Anker, Stefan
    Lindenfeld, Joann
    Ponikowski, Piotr
    Brueckmann, Martina
    Salsali, Afshin
    Welty, Francine
    Clayton, Tim
    Greenberg, Barry
    Konstam, Marvin
    Lees, Kennedy
    Palmer, Mike
    Parhofer, Klaus
    Pedersen, Terje
    Carson, Peter
    Freston, James
    Kaplowitz, Neil
    Lewis, James
    Mann, Johannes
    Petrie, John
    Agostoni, Piergiuseppe
    Butler, Javed
    Desai, Akshay
    Filippatos, Gerasimos
    Howlett, Jonathan
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (07) : 932 - 942
  • [35] The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF)
    Kotooka, Norihiko
    Kitakaze, Masafumi
    Nagashima, Kengo
    Asaka, Machiko
    Kinugasa, Yoshiharu
    Nochioka, Kotaro
    Mizuno, Atsushi
    Nagatomo, Daisuke
    Mine, Daigo
    Yamada, Yoko
    Kuratomi, Akiko
    Okada, Norihiro
    Fujimatsu, Daisuke
    Kuwahata, So
    Toyoda, Shigeru
    Hirotani, Shin-ichi
    Komori, Takahiro
    Eguchi, Kazuo
    Kario, Kazuomi
    Inomata, Takayuki
    Sugi, Kaoru
    Yamamoto, Kazuhiro
    Tsutsui, Hiroyuki
    Masuyama, Tohru
    Shimokawa, Hiroaki
    Momomura, Shin-ichi
    Seino, Yoshihiko
    Sato, Yasunori
    Inoue, Teruo
    Node, Koichi
    HEART AND VESSELS, 2018, 33 (08) : 866 - 876
  • [36] Clinical Outcomes in Patients on Hemodialysis with Congestive Heart Failure
    Zhao, Xinju
    Gan, Liangying
    Niu, Qingyu
    Hou, Fan Fan
    Liang, Xinlin
    Chen, Xiaonong
    Chen, Yuqing
    Zhao, Junhui
    McCullough, Keith
    Ni, Zhaohui
    Zuo, Li
    KIDNEY DISEASES, 2023, 9 (04) : 306 - 316
  • [37] Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial
    IsHak, Waguih William
    Korouri, Samuel
    Darwish, Tarneem
    Vanle, Brigitte
    Dang, Jonathan
    Edwards, Gabriel
    Black, Jeanne T.
    Aronow, Harriet
    Kimchi, Asher
    Spiegel, Brennan
    Hedrick, Rebecca
    Chernoff, Robert
    Diniz, Marcio A.
    Mirocha, James
    Manoukian, Vicki
    Harold, John
    Ong, Michael K.
    Wells, Kenneth
    Hamilton, Michele
    Danovitch, Itai
    PLOS ONE, 2021, 16 (01):
  • [38] Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Poole-Wilson, PA
    Cleland, JGF
    Di Lenarda, A
    Hanrath, P
    Komajda, M
    Metra, M
    Remme, WJ
    Swedberg, K
    Torp-Pedersen, C
    EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (03) : 321 - 329
  • [39] Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
    Ostovaneh, Mohammad Reza
    Poustchi, Hossein
    Hemming, Karla
    Marjani, Hajiamin
    Pourshams, Akram
    Nateghi, Alireza
    Majed, Masoud
    Navabakhsh, Behrouz
    Khoshnia, Masoud
    Jaafari, Elham
    Mohammadifard, Noushin
    Malekzadeh, Fatemeh
    Merat, Shahin
    Sadeghi, Masoumeh
    Naemi, Mohammad
    Etemadi, Arash
    Thomas, G. Neil
    Sarrafzadegan, Nizal
    Cheng, K. K.
    Marshall, Tom
    Malekzadeh, Reza
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (12) : 1609 - 1617
  • [40] Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial
    Massie, Barry M.
    Collins, Joseph F.
    Ammon, Susan E.
    Armstrong, Paul W.
    Cleland, John G. F.
    Ezekowitz, Michael
    Jafri, Syed M.
    Krol, William F.
    O'Connor, Christopher M.
    Schulman, Kevin A.
    Teo, Koon
    Warren, Stuart R.
    CIRCULATION, 2009, 119 (12) : 1616 - 1624